Diabetes Clinical Trials in Springfield
View 15 new treatments for Diabetes in Springfield, IL. Every day, Power helps hundreds of Diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
ILUVIEN® Implant for Diabetic Macular Edema
Alimera Sciences Clinic, Springfield + 1 more
This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Samer Kaba, MD
Study Chair
RYBELSUS® for Type 2 Diabetes
Novo Nordisk Clinic, Gillespie + 3 more
This trial is testing RYBELSUS®, a tablet that lowers blood sugar, in people with type 2 diabetes who need extra treatment. The study will compare RYBELSUS® to other similar tablets over several months. Participants will have regular doctor visits and complete some questionnaires. Pregnant or breastfeeding women cannot join. RYBELSUS® is an oral form of a medication that has been used in injectable form for managing type 2 diabetes.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Clinical Transparency (dept. 1452)
Study Director
Tirzepatide vs Dulaglutide for Type 2 Diabetes
Eli Lilly Clinic, Springfield + 2 more
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
IcoSema for Type 2 Diabetes
Novo Nordisk Clinic, Carlinville + 2 more
This trial will test a new weekly injection called IcoSema, which combines two drugs, in people with type 2 diabetes. The goal is to see if it controls blood sugar better than the existing drug, semaglutide. Participants will be randomly assigned to receive either IcoSema or semaglutide for several months.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Clinical Transparency (dept. 1452)
Study Director
Bevacizumab Safety for Retinal Disease
Outlook Clinic, Springfield + 1 more
The study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Tarcocimab for Diabetic Retinopathy
Kodiak Sciences Clinic, Springfield + 1 more
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.
Recruiting
Phase 3
Est. 4 - 6 Weeks
Pablo Velazquez-Martin, MD
Study Director
Phage Therapy for Diabetic Foot Osteomyelitis
Adaptive Phage Clinic, Springfield + 1 more
This is a phase IIa randomized trial designed to evaluate bacteriophage therapy in patients with diabetic foot osteomyelitis.
Recruiting
Phase 2
Est. 3 - 12 Weeks
Edward Fang
Principal Investigator
Ladarixin for Type 1 Diabetes
Dompé Farmaceutici S.p.A Clinic, Springfield + 1 more
This trial is testing ladarixin, a medication that may help protect insulin-producing cells in the pancreas. It targets adolescents and adults who have been diagnosed with type 1 diabetes, especially those with severe cases. The goal is to see if ladarixin can slow down the progression of the disease and keep these cells working longer.Show More
Waitlist
Phase 2
Est. 6 - 12 Weeks
Francesco Sergio, MD
Study Director
Antimicrobial Peptide Spray for Diabetic Foot
Jiangsu ProteLight Clinic, Springfield + 1 more
This is a Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the clinical efficacy and safety of Antimicrobial Peptide PL-5 Topical Spray in patients with mild infections of diabetic foot ulcers. Eligible subjects will be randomized (1:1:1) to receive twice a day, 14 days treatment of Antimicrobial Peptide PL-5 Topical Spray (1‰), Antimicrobial Peptide PL-5 Topical Spray (2‰) and topical placebo (vehicle) spray. In this study, the cut-off date for final analysis is defined as the time when all subjects have completed the last visit or discontinued the studyShow More
Waitlist
Phase 2
Est. 5 - 8 Weeks
Mingxia Chen, MD, MS
Study Chair
Intensive Education for Managing Type 2 Diabetes and Cardiovascular Disease
Research Clinic, Springfield + 1 more
This trial tests an educational program for healthcare providers to improve care for patients with type 2 diabetes and heart disease by enhancing teamwork and following best practices.Show More
Waitlist
No Placebo Trial
N/A
Est. 3 - 6 Weeks
Christopher Granger, MD
Principal Investigator
Page 1 of 2
Frequently Asked Questions
Explore related conditions